SCHEMBL19674604

SCHEMBL19674604

CON(C)[S+]([O-])c1cncc(Br)c1

nearest known ligand 0.37

Predicted protein targets (top 2)

geneUniProtsupporting neighboursconfidence
POLB P06746 1/20 0.30
HCAR2 Q8TDS4 1/20 0.30

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL19674652 0.82 POLB (0.33) POLBHCAR2
SCHEMBL18845125 0.78 KMT2A (0.32)
SCHEMBL1403825 0.72 POLB (0.36) POLBHCAR2
SCHEMBL30639795 0.68 POLB (0.37) POLBHCAR2
SCHEMBL26614753 0.68 POLB (0.37) POLBHCAR2
SCHEMBL15074479 0.68 POLB (0.33) POLBHCAR2
SCHEMBL21231620 0.66 KDM4E (0.40) POLBHCAR2
SCHEMBL19674732 0.64 KDM4E (0.38) POLBHCAR2
SCHEMBL23087851 0.63 HTT (0.42) POLBHCAR2
SCHEMBL25254715 0.63 MAPT (0.43)

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-2794600-B1 2,3-Dihydro-benzo[1,4]oxazine derivatives and related compounds as phosphoinositide-3 kinase (PI3K) inhibitors for the treatment of e.g. rheumatoid arthritis NOVARTIS AG (CH) 2017-12-06 EP disclosed